This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Kevin Huang
Head, Corporate Strategy and Investment at WuXi Biologics


Dr. Kevin Huang is Chief of Staff, Head of Corporate Strategy and Investment at WuXi Biologics. He leads the company’s global expansion efforts through acquisitions and external collaborations, coordinates new technology evaluation and manages the venture investment of WuXi Biologics. His team is also responsible for corporate communications and provides strategic and operational support to senior management. Before joining WuXi Biologics, Dr. Huang worked on clinical and commercial process life cycle management of Nivolumab (anti-PD1 antibody) and other biologics at Bristol-Myers Squibb, including technology transfer, process validation, and commercial manufacturing. He also has analytical R&D and process development experience at Amgen and AbbVie, and received business training at Morgan Stanley Hong Kong and Roland Berger Shanghai. Dr. Huang holds Ph.D. degree in Pharmaceutical Science from University of Illinois and B.S. degree from Peking University.